FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
 & Lead Plaintiff Deadline - March 28, 2017 - EconoTimes)
NEW YORK, March 28, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Egalet Corporation (“Egalet” or the “Company”) (NASDAQ:EGLT) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Egalet securities between December 15, 2015, and January 9, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/eglt.
The class action lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose material adverse information about its lead product, ARYMO ER and the likelihood that it would receive oral abuse-deterrent labeling.
On January 9, 2017, Egalet released a statement announcing the approval of its product Arymo ER. Later that day, the U.S. Federal Drug Administration stated that a competitor product MorphaBond “has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties.” Following this news, Egalet stock dropped, thus damaging investors.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/eglt or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Egalet you have until March 28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
